B-hPD-L1 plus/hHER2 MC38_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

Please input keywords

Order

*Country

日本

アメリカ

中国

オーストラリア

シンガポール

イギリス

フランス

ドイツ

スイス

イタリア

カナダ

韓国

オランダ

ベルギー

スウェーデン

その他

*Province

*City

*Name

*Telephone

*Company

*Position

*Email

*Verification code

*Verification Code

B-hPD-L1 plus/hHER2 MC38

Common name	B-hPD-L1 plus/hHER2 MC38	Catalog number	321917
Aliases	CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1, CD274 molecule,Programmed cell death 1 ligand 1; ERBB2, CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, erb-b2 receptor tyrosine kinase 2	Disease	Colon carcinoma
Organism	Mouse	Strain	C57BL/6
Tissue types	Colon	Tissue	Colon

Description

The mouse Pdl1 gene was replaced by human PD-L1 coding sequence in B-hPD-L1 plus/hHER2 MC38 cells. Human PD-L1 is highly expressed on the surface of B-hPD-L1 plus/hHER2 MC38 cells.

The mouse Erbb2 gene was replaced by human ERBB2 coding sequence in B-hPD-L1 plus/hHER2 MC38 cells. Human ERBB2 is highly expressed on the surface of B-hPD-L1 plus/hHER2 MC38 cells.

Application

B-hPD-L1 plus/hHER2 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Targeting strategy

Gene targeting strategy for B-hPD-L1 plus/hHER2 MC38 cells.
The exogenous promoter and human PD-L1 coding sequence was inserted to replace part of murine exon 3. The insertion disrupts the endogenous murine Pdl1 gene, resulting in a non-functional transcript.
The exogenous CAG promoter and human ERBB2 coding sequence was inserted to replace part of murine exon 2 and all of exons 3-7. The insertion disrupts the endogenous murine Erbb2 gene, resulting in a non-functional transcript.

Protein expression analysis

from clipboard

PD-L1 and HER2 expression analysis in B-hPD-L1 plus/hHER2 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hPD-L1 plus/hHER2 MC38 cultures were stained with species-specific anti-PD-L1 and anti-HER2 antibody. Human PD-L1 and HER2 were detected on the surface of B-hPD-L1 plus/hHER2 MC38 cells but not wild-type MC38 cells. The 3-B08 clone of B-hPD-L1 plus/hHER2 MC38 cells was used for in vivo tumor growth assays.

Tumor growth curve & Body weight changes

from clipboard

Subcutaneous homograft tumor growth of B-hPD-L1 plus/hHER2 MC38 cells. B-hPD-L1 plus/hHER2 MC38 cells (5x10⁵) and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into C57BL/6 mice (female, 9-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean ± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hPD-L1 plus/hHER2 MC38 cells were able to form tumors in vivo and can be used for efficacy studies.

Tumor growth curve of individual mice

from clipboard

B-hPD-L1 plus/hHER2 MC38 MC38 tumor cells growth of individual mice. B-hPD-L1 plus/hHER2 MC38 cells (5x10⁵) and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into C57BL/6 mice (female, 9-week-old, n=6). As shown in panel, B-hPD-L1 plus/hHER2 MC38 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

from clipboard

B-hPD-L1 plus/hHER2 MC38 cells were subcutaneously transplanted into C57BL/6 mice (n=6), and on 39 days post inoculation, tumor cells were harvested and assessed for human PD-L1 and HER2 expression by flow cytometry. As shown, human PD-L1 and HER2 were highly expressed on the surface of tumor cells. Therefore, B-hPD-L1 plus/hHER2 MC38 cells can be used for in vivo efficacy studies of PD-L1 and HER2 therapeutics.

Tumor growth curve & Body weight changes

from clipboard

Subcutaneous homograft tumor growth of B-hPD-L1 plus/hHER2 MC38 cells. B-hPD-L1 plus/hHER2 MC38 cells (2x10⁵, 5x10⁵) and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into homozygous B-hHER2 mice (female, 5-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean ± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hPD-L1 plus/hHER2 MC38 cells were able to form tumors in vivo and can be used for efficacy studies.

Tumor growth curve of individual mice

from clipboard

B-hPD-L1 plus/hHER2 MC38 MC38 tumor cells growth of individual mice. B-hPD-L1 plus/hHER2 MC38 cells (2x10⁵, 5x10⁵) and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into homozygous B-hHER2 mice (female, 5-week-old, n=6). As shown in panel, B-hPD-L1 plus/hHER2 MC38 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

Tumor volume and weight measurements

from clipboard

Protein expression analysis of tumor cells

from clipboard

B-hPD-L1 plus/hHER2 MC38 cells were subcutaneously transplanted into homozygous B-hHER2 mice (n=6), and on 30 days post inoculation, tumor cells were harvested and assessed for human PD-L1 and HER2 expression by flow cytometry. As shown, human PD-L1 and HER2 were highly expressed on the surface of tumor cells. Therefore, B-hPD-L1 plus/hHER2 MC38 cells can be used for in vivo efficacy studies of PD-L1 and HER2 therapeutics.